Evaluating the safety and efficacy of plasma therapy/plasmapheresis for systemic sclerosis - A comprehensive systematic review

被引：0

作者：

Bano, Saira ^{[1
]}

Jawed, Inshal ^{[2
]}

Qadir, Muhammad umair abdul ^{[2
]}

Rizvi, Syed Ali Farhan Abbas ^{[3
]}

Karmani, Vikash Kumar ^{[4
]}

Alam, Farah ^{[2
]}

Haseeb, Abdul ^{[4
]}

Khan, Hina ^{[5
]}

Mirza, Agha Muhammad Wali ^{[3
]}

Akhtar, Naheed ^{[1
]}

Bin Gulzar, Abu Huraira ^{[6
]}

Ahmed, Khabab Abbasher Hussien Mohamed ^{[7
]}

机构：

[1] Bahria Univ Med & Dent Coll, Karachi 44000, Pakistan

[2] Dow Univ Hlth Sci, Karachi 74200, Pakistan

[3] Jinnah Med & Dent Coll, Karachi 75510, Sindh, Pakistan

[4] Jinnah Sindh Med Univ, Karachi 75510, Pakistan

[5] Jinnah Postgrad Med Ctr, Karachi 75510, Pakistan

[6] Serv Inst Med Sci, Lahore, Pakistan

[7] Univ Khartoum, Fac Med, Khartoum 11111, Sudan

来源：

TRANSFUSION AND APHERESIS SCIENCE | 2025年 / 64卷 / 01期

关键词：

Plasma Therapy; Plasmapheresis; Systemic Sclerosis; Diffuse Sclerosis; Treatment; CONNECTIVE-TISSUE DISEASE; PULMONARY ARTERIAL-HYPERTENSION; SCLERODERMA RENAL CRISIS; LOCALIZED SCLERODERMA; INCREASED EXPRESSION; EXCHANGE; PLASMAPHERESIS; FIBROBLASTS; CLASSIFICATION; COMPLICATIONS;

D O I：

10.1016/j.transci.2024.104036

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Systemic sclerosis (SSc) is an autoimmune disorder with fibrosis in multiple organs, autoantibodies, and microvascular abnormalities. Its origin is unclear, but it may result from circulatory damage, collagen metabolism disruption, and modifications in immunoregulation. The disease affects various organs and has high morbidity and mortality rates. SSc-related complications are managed using immunosuppressive medications that target autoantibodies. The main objective of this study was to assess the safety and efficacy of plasma therapy/plasmapheresis in managing SSc. Methods: This systematic review followed PRISMA and IMRAD guidelines, using PICO framework for study selection based on MeSH terms and Boolean operators. It included cross-sectional, randomized control trials, and clinical studies on plasma therapy for SSc. Standardized protocols were used for data extraction and risk of bias assessment. Discussion: Plasma therapy is a growing treatment option for managing SSc with reported benefits, especially in early stages and specific organ complications. However, further investigation and standardized protocols are needed. This review explores the potential of plasma therapy in improving the quality of life for SSc patients and in combination with other treatments. Result: The review analyzed 15 articles, including research papers, controlled trials, and case reports. Plasma therapy, involving Plasmapheresis and therapeutic plasma exchange (TPE), improved symptoms of SSc like Raynaud phenomenon, vasculitis, muscle dysfunction, and digital ulcers. However, outcomes varied among studies, and some advanced cases showed limited benefits. Conclusion: Plasma therapy can be an effective way of managing the symptoms of systemic sclerosis with low incidence of adverse events. However, the exact mechanism behind this treatment is still unclear. Therefore, additional studies are required.

引用

页数：8

共 62 条

[1] Angiographically proven coronary artery disease in scleroderma [J].